Ignite Creation Date:
2024-05-06 @ 4:02 AM
Last Modification Date:
2024-10-26 @ 11:42 AM
Study NCT ID:
NCT02437786
Status:
COMPLETED
Last Update Posted:
2018-01-17
First Post:
2015-01-05
Brief Title:
Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX
Sponsor:
ALK-Abelló AS
Organization:
ALK-Abelló AS
Study Overview
Official Title:
Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX
Status:
COMPLETED
Status Verified Date:
2018-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GT-20
Brief Summary:
The specific clinical trial is a part in which ALK- Abelló will directly work to explore human immunological mechanisms of SIT observed after GRAZAX treatment
Detailed Description:
The main idea of the project was to address the study of some of the most important inflammatory diseases psoriasis rheumatoid arthritis lupus rhinitisasthma with the aim of identifying novel inflammatory markers
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None